SCHEMBL2974690

SCHEMBL2974690

[CH2]c1ccc(C(=O)N(C)Cc2ccccc2OC)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.66
KMT2A Q03164 4/20 0.66
CRHBP P24387 1/20 0.54
CRHR2 Q13324 1/20 0.54
NPC1 O15118 2/20 0.54
TDP1 Q9NUW8 2/20 0.52
POLB P06746 1/20 0.50
GAA P10253 1/20 0.50
ALDH1A1 P00352 1/20 0.49
ATM Q13315 1/20 0.49
TACR1 P25103 1/20 0.48
BCHE P06276 2/20 0.48
ACHE P22303 2/20 0.48
HTT P42858 1/20 0.48
PPARD Q03181 1/20 0.47
LIMK2 P53671 1/20 0.47
TAS2R14 Q9NYV8 2/20 0.47
CHRM2 P08172 1/20 0.47
CHRM1 P11229 1/20 0.47
HPGD P15428 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL96528 0.84 LPAR1 (0.54) MEN1KMT2AALDH1A1TACR1ACHE
SCHEMBL19501280 0.79 PPARD (0.70) PPARD
SCHEMBL6583786 0.76 MEN1 (0.62) MEN1KMT2ACRHBPCRHR2NPC1
SCHEMBL6583793 0.76 MEN1 (0.62) MEN1KMT2ACRHBPCRHR2NPC1
SCHEMBL95409 0.75 TNKS (0.45) MEN1KMT2APOLBALDH1A1HPGD
SCHEMBL14540454 0.75 MEN1 (0.74) MEN1KMT2ACRHBPCRHR2NPC1
SCHEMBL94368 0.73 HDAC1 (0.77) POLBGAAALDH1A1HTTHPGD
SCHEMBL5320162 0.71 HPGD (0.41) MEN1KMT2ATDP1POLBALDH1A1
SCHEMBL95796 0.71 POLB (0.40) MEN1KMT2ANPC1TDP1POLB
SCHEMBL17882308 0.70 RIPK1 (0.66) MEN1KMT2ACRHBPCRHR2TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362252-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-01-29 US disclosed
EP-1797082-B1 CARBOSTYRIL COMPOUND OTSUKA PHARMA CO LTD (JP) 2012-08-29 EP disclosed
US-20100261705-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. 2010-10-14 US disclosed
US-7777038-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-08-17 US disclosed
US-20090326008-A1 NF-kappa B Inhibitor OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2009-12-31 US disclosed
EP-2043644-A1 NF- B INHIBITOR Otsuka Pharmaceutical Co., Ltd. (JP) 2009-04-08 EP disclosed
WO-2008010601-A1 NF- ϰB INHIBITOR OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2008-01-24 WO disclosed
US-20070179173-A1 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-02 US disclosed
EP-1797082-A1 CARBOSTYRIL COMPOUND Otsuka Pharmaceutical Company, Limited (JP) 2007-06-20 EP disclosed
WO-2006035954-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-04-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090326008-A1 NF-kappa B Inhibitor NFKBIA, NFKB2, IKBKB MEN1 4401/4885KMT2A 1059/4885CRHBP 924/4885
US-20070179173-A1 Carbostyril compound GTF2F1, F3, GTF2F2 MEN1 3912/4885KMT2A 2732/4885CRHBP 1779/4885
US-20100261705-A1 CARBOSTYRIL COMPOUND GTF2F1, F3, GTF2F2 MEN1 3912/4885KMT2A 2732/4885CRHBP 1779/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.